In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status
- PMID: 34058113
- DOI: 10.7326/ACPJ202106150-068
In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status
Abstract
Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation. 2021;143:310-21. 33095032.
Comment on
-
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.Circulation. 2021 Jan 26;143(4):310-321. doi: 10.1161/CIRCULATIONAHA.120.051685. Epub 2020 Oct 23. Circulation. 2021. PMID: 33095032 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical